Treatment of Digital Ulcers in Systemic Sclerosis Using Bone Marrow-Derived Mesenchymal Stromal Cells The MANUS Trial
A Randomized, Double-Blind Study with Intramuscular Injections
Led by UMC Utrecht · Updated on 2025-09-10
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and potential benefits of injecting allogeneic mesenchymal stromal cells into muscles as a treatment for digital ulcers caused by systemic sclerosis. This randomized, double-blind, placebo-controlled trial focuses on patients whose ulcers have not improved with standard treatments like intravenous prostacyclins. The study aims to understand how the treatment affects toxicity and other health outcomes over time.
Participants will be randomly assigned to receive eight intramuscular injections of either bone marrow-derived mesenchymal stromal cells or a placebo into the most affected hand or forearm. The injections will be administered by experienced clinicians using blinded syringes. The treatment group receives 45 to 50 million cells suspended in a saline and human serum albumin solution. Follow-up visits will take place at several intervals up to one year after treatment.
Throughout the study, participants will undergo assessments including safety monitoring for local and systemic side effects, pain levels, ulcer healing, skin condition, hand function, and quality of life. Researchers will also examine changes in blood and tissue markers related to inflammation, blood vessel health, and immune response. These evaluations will occur at scheduled visits ranging from 48 hours to 52 weeks after treatment, allowing for comprehensive monitoring of both short- and long-term effects.
CONDITIONS
Brief Title
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
Research Team
F
Femke van Rhijn, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Established diagnosis of systemic sclerosis according to the 2013 ACR/EULAR criteria
At least one active digital ulcer larger than 2 mm with visible depth and loss of dermis
Ulcer must be refractory to intravenous prostacyclin treatment, defined by worsening, no improvement after 2 months, or recurrence within 3 months
Written informed consent provided
You will not qualify if you...
Ulcer with underlying calcinosis confirmed by X-ray
History of cancer or malignancy within the past 10 years
Pregnancy or unwillingness to use effective contraception during the study
Serious concomitant disease with life expectancy less than 1 year
Uncontrolled hypertension
Uncontrolled acute or chronic infection with systemic symptoms such as fever
Inability to attend follow-up visits
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single treatment day
Participants receive intramuscular injections of either mesenchymal stromal cells or placebo in the most affected limb.
1 visit for injection (in-person)
Follow-up
Duration - 52 weeks after treatment
Participants are monitored for treatment effects, toxicity, healing of ulcers, pain, quality of life, and other health parameters.
8 visits at 48 hours, and 2, 4, 8, 12, 24, and 52 weeks post-treatment (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 1 Study to Assess Safety and Effects of XmAb657 Injection in Healthy Adults and Adults With Autoimmune Diseases Including Idiopathic Inflammatory Myopathies, Systemic Sclerosis, and Sjogrens Disease
Study of NKX019, a CAR NK Cell Therapy Targeting CD19, in Adults With Autoimmune Diseases
Phase 1 Study Evaluating Safety and Preliminary Effects of CTX112, a CRISPR-Cas9 Engineered CD19-Targeting T Cell Therapy, in Adults with Refractory Autoimmune Diseases
Phase 1b2 Study of AZD0120 Dual Targeting CAR T-cell Therapy in Adults with Autoimmune Diseases Including Systemic Sclerosis and Rheumatoid Arthritis
Nemolizumab Treatment Study for Adults with Systemic Sclerosis
A 52-Week Randomized, Placebo-Controlled, Dose-Finding Phase 2 Trial
Phase 1 Study of ALLO-329, a Dual Anti-CD19Anti-CD70 CAR T Cell Therapy, Evaluating Safety and Early Effects in Adults with Autoimmune Diseases
A Double-Blind Randomized Trial of Oral Nerandomilast Versus Placebo to Evaluate Efficacy and Safety in Systemic Sclerosis
Open-Label Phase 1 Study to Assess Safety, Tolerability, and Immune Effects of Intravenous HBM7020 in Healthy Adults and Adults With Autoimmune Diseases
Exploratory Study Evaluating Safety and Initial Effectiveness of YTS109 Cell Injection in Adults with Recurrent or Refractory Autoimmune Diseases
Study of Skin Cells and Immune System in Adults with Systemic Sclerosis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.
Femke C C van Rhijn-Brouwer, Hendrik Gremmels, Joost O Fledderus...